Esophageal Cancer Clinical Trial
Vaccine Therapy in Treating Patients With Advanced or Recurrent Cancer
Summary
RATIONALE: Vaccines made from certain human papillomaviruses may be able to help the body to kill more tumor cells.
PURPOSE: Phase II trial to study the effectiveness of human papillomavirus vaccine therapy in treating patients who have advanced or recurrent cancer of the cervix, vagina, penis, anus, esophagus, or head and neck.
Full Description
OBJECTIVES:
Determine whether endogenous cellular immunity to the viral oncoproteins human papilloma virus 16 (HPV16) E6 and E7 is present in patients with advanced or recurrent carcinoma of the cervix or other carcinomas that carry HPV16.
Determine whether vaccination with antigen-presenting cells pulsed with synthetic peptide corresponding to the tumor's HPV16 E6 or E7 peptide can induce or boost patient cellular immunity to that particular peptide.
Determine the type and characteristics of the cellular immunity generated in patients treated with this regimen.
Determine the toxicity of this regimen in these patients.
Determine the tumor response in patients treated with this regimen.
Determine whether in vivo T cells generated specifically against HPV16 E6 or E7 peptide can be cloned and expanded in vitro against the corresponding peptide.
OUTLINE: Patients are stratified according to disease category as defined by the following:
Stratum A: Stage III cervical cancer not previously treated with appropriate radiotherapy; stage IV or recurrent cervical cancer; or other advanced tumors that harbor human papilloma virus 16 (HPV16) such as anogenital, esophageal, or head and neck cancers.
Stratum B: Stage III cervical cancer previously treated with standard therapy with no evidence of residual disease. Vaccination in this group is given as adjuvant therapy.
Patients are assigned to receive HPV E6 or E7 peptide by the principal investigator. Peripheral blood mononuclear cells (PBMC) (antigen presenting cells) are harvested and treated in vitro with sargramostim (GM-CSF) and pulsed with HPV16 E6 or E7. Patients receive vaccination with HPV16 E6 or E7 pulsed PBMC IV over 1-2 minutes during weeks 1, 3, 7, and 11 for a total of 4 vaccinations. Treatment continues in the absence of disease progression or unacceptable toxicity. Patients who achieve complete response (CR) continue treatment for a maximum of 1 year past CR.
Patients are followed at 1 month.
PROJECTED ACCRUAL: A total of 40-46 patients (at least 28 patients for stratum A and 12 for stratum B) will be accrued for this study within 1-2 years.
Eligibility Criteria
DISEASE CHARACTERISTICS:
Histologically proven stage III, IV, or recurrent carcinoma of the cervix or other tumor that carries human papilloma virus 16 (HPV16) such as other anogenital (vulvar, penile, and anal), esophageal, and head and neck cancers
HLA-A2.1 positive
Patients with tumors other than cervical cancer must have no other therapeutic options
Fresh tissue or paraffin block available for HPV genome detection and typing (optional for cervical cancer)
No history of CNS metastases
PATIENT CHARACTERISTICS:
Age:
Over 18
Performance status:
ECOG 0-1
Life expectancy:
More than 3 months
Hematopoietic:
WBC at least 2,000/mm^3
Platelet count at least 100,000/mm^3
Hepatic:
Bilirubin no greater than 2.0 mg/dL
SGPT no greater than 4 times normal
Renal:
Creatinine no greater than 2.0 mg/dL
Cardiovascular:
No myocardial infarction within the past 6 months
No New York Heart Association class III or IV heart disease
Immunologic:
No autoimmune disease, e.g.:
Systemic lupus erythematosus
Multiple sclerosis
Ankylosing spondylitis
HIV negative
Responsive to 1 of the following skin test antigens:
Mumps Trichophyton
Candida Tetanus
Other:
No active infection requiring antibiotics
No weight loss greater than 20% within the past 6 months
No other active malignancy except basal cell skin cancer
Not pregnant or nursing
Negative pregnancy test
Fertile patients must use effective contraception
PRIOR CONCURRENT THERAPY:
Biologic therapy:
At least 4 weeks since prior immunotherapy and recovered
Chemotherapy:
At least 4 weeks since prior chemotherapy and recovered
Endocrine therapy:
At least 4 weeks since prior steroids and recovered
Radiotherapy:
At least 4 weeks since prior radiotherapy and recovered
Surgery:
Not specified
Other:
Recovered from the toxic effects of prior therapy
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There are 5 Locations for this study
Bethesda Maryland, 20892, United States
Bethesda Maryland, 20892, United States
Boston Massachusetts, 02114, United States
Boston Massachusetts, 02115, United States
Morristown New Jersey, 07962, United States
Galveston Texas, 77555, United States
How clear is this clinincal trial information?
Please confirm you are a US based health care provider:
Yes, I am a health care Provider No, I am not a health care providerSign Up Now.
Take Control of Your Disease Journey.
Sign up now for expert patient guides, personalized treatment options, and cutting-edge insights that can help you push for the best care plan.